1283 York AvenueNew York, NY 10065
Overview of Dr. Andreopoulou
I am a Professor of Medicine and the Director of Breast Cancer Clinical Research at Weill Cornell Medicine/NewYork-Presbyterian Hospital where I specialize in the personalized multidisciplinary care and treatment of patients with breast cancer. I am also a member of the Englander Institute for Precision Medicine at Cornell. I previously held faculty positions at the Albert Einstein College of Medicine/ Montefiore Medical Center and the University of Texas M.D. Anderson Cancer Center. I completed my training in major academic institutions in both Europe and the U.S., including St Bartholomew’s Hospital and the Royal Marsden Hospital/Institute of Cancer Research in London, UK and the New York University School of Medicine. I was a European Society of Medical Oncology fellow. I have a special interest in individualization of patient treatment and particularly in caring for women with aggressive breast cancer. My main research interest involves precision medicine to fast-track the drug development of biologics and targeted therapy that exploit our knowledge of the cancer genome and the immuno cell network for immunotherapy in order to effectively manage, treat and cure breast cancer. I am involved with all phases of clinical drug development in all stages of the disease and I especially focus on innovative clinical trial design that incorporates cutting-edge technology.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2005 - 2008- NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2007
University of Ioannina Faculty of MedicineClass of 1994, MD, Cum Laude
Certifications & Licensure
NY State Medical License 2007 - 2026
TX State Medical License 2008 - 2011
ECFMG
Awards, Honors, & Recognition
- Professor of Clinical Medicine Weill Cornell Medicine, 2022
- Associate Professor of Medicine Albert Einstein College of Medicine, 2013
- Assistant Professor of Medicine, Department of Breast Medical Oncology UT. MD Anderson Cancer Center, 2007-2010
- Join now to see all
Clinical Trials
- Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer Start of enrollment: 2010 Nov 22
- Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2011 May 02
- A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
- Join now to see all
Publications & Presentations
PubMed
- Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Co...Letizia Pontolillo, Andrew A Davis, Lorenzo Gerratana, Arielle J Medford, Judy Wang
NPJ Breast Cancer. 2025-08-16 - 15 citationsDirect sensing of dietary ω-6 linoleic acid through FABP5-mTORC1 signaling.Nikos Koundouros, Michal J Nagiec, Nayah Bullen, Evan K Noch, Guillermo Burgos-Barragan
Science. 2025-03-14 - 2 citations[18F]-Fluoroestradiol (FES) brain PET in the evaluation of patients with estrogen receptor positive breast cancer and known or suspected brain metastases.Jana Ivanidze, Arman Sharbatdaran, Aliah McCalla, Andrew Brandmaier, Eleni Andreopoulou
European Journal of Radiology. 2024-12-01
Press Mentions
- Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast CancerJanuary 22nd, 2021
EMBCA Presents Evolution of Pharma and Biotech Industry in the 21st CenturyNovember 23rd, 2019
One-Way Texting: No Help with Breast Cancer Pill Taking, But…July 25th, 2019
Professional Memberships
- Member
Other Languages
- Greek
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
